10-Q: Oscar Health Reports Strong Membership Growth and Improved Financial Performance in Q3 2024

Oscar Health's Q3 2024 results show significant membership growth and improved financial metrics, despite a net loss for the quarter.

Summary

• Oscar Health reported a net loss of $54.4 million for the third quarter of 2024, compared to a net loss of $65.7 million in the same period of 2023.
• The company's total revenue increased to $2.42 billion, up from $1.44 billion in Q3 2023, driven by a significant rise in premium revenue.
• Membership grew to approximately 1.65 million as of September 30, 2024, a 68% increase compared to the same period last year.
• The Medical Loss Ratio (MLR) was 84.6% for the quarter, slightly higher than 83.8% in Q3 2023, but improved to 79.5% for the nine months ended September 30, 2024, compared to 80.0% for the same period in 2023.
• The Selling, General, and Administrative (SG&A) Expense Ratio improved to 19.0% for the quarter, down from 22.6% in Q3 2023.
• Adjusted EBITDA was a loss of $11.6 million for the quarter, compared to a loss of $20.3 million in Q3 2023, but was a profit of $311.9 million for the nine months ended September 30, 2024, compared to a profit of $66.4 million for the same period in 2023.
• The company's investment portfolio saw an increase in income due to a larger asset base and higher interest rates.

Sentiment

Score: 7

Explanation: The document shows strong growth in membership and revenue, along with improvements in key financial metrics like MLR and SG&A ratio. However, the net loss for the quarter and the exit from the small group market temper the overall positive outlook. The company is making progress but still has challenges to overcome.

Positives

• Membership has grown significantly, indicating strong market demand for Oscar's health plans.
• Total revenue has increased substantially, reflecting the company's ability to generate more income.
• The Medical Loss Ratio (MLR) has improved over the nine-month period, suggesting better cost management.
• The Selling, General, and Administrative (SG&A) Expense Ratio has decreased, indicating improved operational efficiency.
• Adjusted EBITDA has turned positive for the nine-month period, showing a move towards profitability.
• Investment income has increased, contributing to overall revenue growth.
• The company's health insurance subsidiaries are in compliance with and in excess of minimum capital requirements.

Negatives

• Oscar Health reported a net loss of $54.4 million for the third quarter of 2024.
• The Medical Loss Ratio (MLR) increased slightly for the quarter compared to the same period last year.
• The company is exiting the small group market and not renewing its partnership with Cigna after December 31, 2024.

Risks

• The company's risk adjustment transfer estimates are subject to a high degree of estimation and variability.
• The company is subject to various regulatory reviews and legal proceedings, which could result in fines or changes to business practices.
• The company's business is affected by seasonal patterns, with medical expenses typically higher in the second half of the year.
• The company's reinsurance agreements do not relieve it of its primary medical claims incurred obligations.
• The company's convertible senior notes due 2031 are now convertible at the option of the holder, which could impact the company's capital structure.
• The company is exposed to interest rate risk, which could impact the fair value of its investment portfolio.

Future Outlook

The company expects continued growth in the ACA marketplace due to Medicaid redeterminations and is focused on managing costs and improving operational efficiency. The company is also focused on the transition of the Cigna+Oscar partnership and the exit from the small group market.

Management Comments

• Management believes that the company's operational and financial measures are useful in evaluating performance.
• Management believes that the company's reinsurance agreements help achieve important goals for the business, including risk management and capital efficiency.
• Management believes that the company's cash, cash equivalents, and investments will be sufficient to fund operating requirements for at least the next twelve months.

Industry Context

The health insurance industry is experiencing significant changes due to regulatory updates, market dynamics, and technological advancements. Oscar Health's focus on technology and member-first philosophy positions it to compete in this evolving landscape. The company's exit from the small group market and non-renewal of the Cigna partnership reflects a strategic shift towards focusing on its core individual market.

Comparison to Industry Standards

• Oscar Health's membership growth of 68% year-over-year is significantly higher than the industry average, indicating strong market acceptance of its plans.
• The company's MLR of 79.5% for the nine months ended September 30, 2024, is within the range of industry benchmarks for health insurance companies, but the slight increase in the quarterly MLR indicates a need for continued cost management.
• The improvement in the SG&A Expense Ratio to 19.0% suggests that Oscar Health is becoming more efficient in its operations compared to some of its peers.
• The company's Adjusted EBITDA of $311.9 million for the nine months ended September 30, 2024, is a positive sign, but the quarterly loss indicates that the company still needs to improve its profitability.
• Compared to established players like UnitedHealth Group and Anthem, Oscar Health is still in a growth phase, focusing on expanding its market share and improving its financial metrics. However, Oscar's technology-driven approach differentiates it from traditional insurers.

Legal Proceedings

• The company is involved in a securities class action lawsuit related to its IPO.
• The company is subject to various regulatory reviews and legal proceedings in the ordinary course of business.

Related Party Transactions

• The company issued convertible senior notes to funds affiliated with or advised by Dragoneer Investment Group, LLC, Thrive Capital Management, LLC, LionTree Investment Management, LLC and Tenere Capital LLC.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and strategic decisions.
• Employees may be impacted by changes in the company's operations and strategic direction.
• Customers (members) may be impacted by changes in the company's health plans and services.
• Suppliers and providers may be impacted by changes in the company's business arrangements.

Next Steps

• The company will continue to focus on managing costs and improving operational efficiency.
• The company will continue to monitor regulatory developments and adapt to changes in the healthcare landscape.
• The company will focus on the transition of the Cigna+Oscar partnership and the exit from the small group market.
• The company will continue to evaluate its capital structure and may consider options for deploying excess capital.

Key Dates

Keywords

health insurance, membership growth, medical loss ratio, adjusted EBITDA, revenue, reinsurance, risk adjustment, healthcare technology, financial results, quarterly report